Ramoplanin

From Self-sufficiency
Revision as of 10:05, 13 August 2009 by Anypodetos (Talk) (No ATC code; minor copyedit)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Ramoplanin
File:Ramoplanin A2.svg
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
Identifiers
CAS Number 76168-82-6
ATC code none
PubChem CID 16132338
Chemical data
Formula C106H170ClN21O30
Molar mass 2254.05 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Ramoplanin (INN) is a glycolipodepsipeptide antibiotic drug derived from strain ATCC 33076 of Actinoplanes.[1]

Mechanism

It exerts its bacteriocidal effect by inhibiting cell wall biosynthesis, acting by inhibiting the transglycosylation step of peptidoglycan synthesis.[2]

Uses

Its development has been fast tracked by the U.S. Food and Drug Administration as a treatment for multi-antibiotic resistant Clostridium difficile infection of the gastrointestinal tract,[3] although it is unstable in the bloodstream and so can only be taken orally against GI tract infections.[4][5][6]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
Intracellular
inhibit peptidoglycan subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin) · DADAL/AR inhibitors (Cycloserine) · bactoprenol inhibitors (Bacitracin)
Glycopeptide
inhibit PG chain elongation: Vancomycin# (Oritavancin, Telavancin) · Teicoplanin (Dalbavancin) · Ramoplanin
β-lactams/
(inhibit PBP
cross-links)
Combinations
Other

M: BAC

drug(J1p, w, n, m, vacc)

50px This systemic antibacterial-related article is a stub. You can help ssf by expanding it.
  1. ↑ Farver DK, Hedge DD, Lee SC. Ramoplanin: a lipoglycodepsipeptide antibiotic. Annals of Pharmacotherapy. 2005 May;39(5):863-8. PMID 15784805
  2. ↑ Fang X, Tiyanont K, Zhang Y, Wanner J, Boger D, Walker S. The mechanism of action of ramoplanin and enduracidin. Molecular Biosystems. 2006 Jan;2(1):69-76. PMID 16880924
  3. ↑ Fulco P, Wenzel RP. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Review of Anti Infective Therapy. 2006 Dec;4(6):939-45. PMID 17181409
  4. ↑ Scheinfeld N. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. Journal of Drugs in Dermatology. 2007 Jan;6(1):97-103. PMID 17373167
  5. ↑ Balagopal A, Sears CL. Clostridium difficile: new therapeutic options. Current Opinion in Pharmacology. 2007 Oct;7(5):455-8. PMID 17644040
  6. ↑ Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clinical Infectious Diseases. 2008 Jan 15;46 Suppl 1:S32-42. PMID 18177219
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Ramoplanin&oldid=23464"